Mercilon's sales fell 16%

The OTC contraceptive market is fluctuating

Yuhan & Ildong discontinued joint sales and launched their own products such as Senseday and Daon

The prolonged out-of-stock of MYVLAR, the second-largest sales item, is benefiting from Melian and Minulet

The OTC oral contraceptives market is fluctuating.

 

Sales of Mercilon and MYVLAR, the existing No.

 

1 and 2 items, declined significantly for each reason.

 

Sales of new products such as Senseday and Daon succeeded in establishing a very stable market.

 

The cause of the change in the market is the change of vendor and the launch of new products.

 

Mercilon and Alesse's sales have changed in the last two years, and Yuhan and Ildong launched their own items and joined them as generic companies.

 

Another reason is the long-term out-of-stock and the resulting base effect.

 

As MYVLAR sold out for more than a year, sales of Melian and Minulet increased.

 

◆Mercilon ↓16%·Alesse ↓15% & ↑ sales of Senseday and Daon According to the drug market research agency IQVIA on the 8th, last year, Alvogen Korea Mercilon posted the most sales among OTC oral pre-contraceptives last year.

 

Mercilon's sales last year were ₩7.7 billion.

 

However, compared to ₩9.1 billion in 2019, it has decreased by 16%.

 

From 2018 (₩9.9 billion), sales declined for the second consecutive year.

 

It is analyzed that the change of the retailer and the addition of generics have had an effect.

 

Mercilon, which is owned by Alvogen Korea, has been sold by Yuhan since May 2016.

 

However, the sales contract ended in May 2019.

 

It was sold by Chong Kun Dang instead of Yuhan.

 

Unfortunately, sales have been falling since Chong Kun Dang took over the sales.

 

Mercilon, which had quarterly sales of the second half of ₩2 billion until the second quarter of 2019, declined to the second half of the ₩1 billion from the third quarter of 2019.

 

In the pharmaceutical industry, intensifying competition due to the addition of generics is also affecting the decline in sales.

 

In recent years, generics have been released in the oral contraceptive market.

 

The most representative product is Yuhan's Senseday.

 

Yuhan released Senseday as its own item after ending the sale of Mercilon.

 

Senseday posted ₩1.3 billion in sales last year.

 

It quickly rose to fourth place.

 

It is analyzed that Alesse, the third-largest item in the market, was also affected by the change of sales location.

 

Alesse's sales last year were ₩1.8 billion, down 15% from ₩2.1 billion in 2019.

 

Ildong was in charge of distribution and sales of Alesse.

 

However, the sales contract ended in December 2019.

 

Currently, it is known that Pfizer is in charge of direct sales.

 

Ildong released Daon and Baraon as their own products after ending the sale of Alesse.

 

This is the same strategy as Yuhan launched Senseday.

 

The two products launched in the second quarter of last year generated total sales of ₩700 million.

 

Daon entered the 7th place in the market in its first year of launch.

 

◆Last year's sales of zero, Melian and Minulet sales increased due to prolonged sales of MYVLAR Dong-A's MYVLAR, which was in second place until 2019, continues to be sold out.

 

MYVLAR has been out of stock since the second half of 2019.

 

Accordingly, sales from ₩3.9 billion in 2018 decreased to ₩2.7 billion in 2019, and last year, as inventory was exhausted, it decreased to less than ₩10 million.

 

Bayer's overseas plant, which supplies the product, was relocated, resulting in a disruption in production.

 

Not only MYVLAR, but also Minivlar & Melian were sold out.

 

Fortunately, supply of Melian has resumed, but MYVLAR and Minivlar are still out of stock.

 

Dong-A focused on selling Melian, which had normalized supply, as a substitute for MYVLAR.

 

It is ranked second in the market with ₩1.8 billion in sales last year.

 

However, MYVLAR is still out of stock.

 

MYVLAR has generated sales of around ₩1 billion each quarter, while Melian's sales are limited to around ₩500 million despite Dong-A's sales power.

 

Pfizer's Minulet received the most due to the sold-out of MYVLAR.

 

Minulet's sales last year were ₩700 million, an increase of 119% from ₩300 million in 2019.

 

Minulet, like MYVLAR, contains ethinylestradiol 0.03mg and gestoden 0.075mg.

 

Minulet is the only product sold in Korea.